What is HC Wainwright’s Estimate for UNCY Q1 Earnings?

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Research analysts at HC Wainwright reduced their Q1 2025 earnings per share estimates for shares of Unicycive Therapeutics in a report released on Tuesday, April 1st. HC Wainwright analyst E. Arce now expects that the company will earn ($0.08) per share for the quarter, down from their previous forecast of ($0.07). HC Wainwright currently has a “Buy” rating and a $7.50 price target on the stock. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.23) per share. HC Wainwright also issued estimates for Unicycive Therapeutics’ Q1 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($0.35) EPS, FY2025 earnings at ($0.35) EPS, FY2026 earnings at $0.92 EPS, FY2026 earnings at $0.92 EPS, FY2027 earnings at $1.98 EPS, FY2027 earnings at $1.98 EPS, FY2028 earnings at $1.19 EPS and FY2029 earnings at $1.34 EPS.

Unicycive Therapeutics (NASDAQ:UNCY) last posted its quarterly earnings results on Thursday, March 27th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13).

Unicycive Therapeutics Stock Down 12.6 %

Unicycive Therapeutics stock opened at $0.52 on Friday. The company has a market capitalization of $53.55 million, a PE ratio of -0.53 and a beta of 2.26. The firm’s fifty day moving average is $0.58 and its 200 day moving average is $0.57. Unicycive Therapeutics has a 12-month low of $0.20 and a 12-month high of $1.49.

Hedge Funds Weigh In On Unicycive Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Nantahala Capital Management LLC grew its stake in shares of Unicycive Therapeutics by 268.5% in the 4th quarter. Nantahala Capital Management LLC now owns 10,391,994 shares of the company’s stock valued at $8,253,000 after buying an additional 7,571,636 shares during the period. Octagon Capital Advisors LP boosted its holdings in Unicycive Therapeutics by 16.8% in the fourth quarter. Octagon Capital Advisors LP now owns 10,000,000 shares of the company’s stock worth $7,942,000 after acquiring an additional 1,441,000 shares in the last quarter. Vivo Capital LLC grew its stake in Unicycive Therapeutics by 123.0% in the fourth quarter. Vivo Capital LLC now owns 9,970,152 shares of the company’s stock valued at $7,918,000 after acquiring an additional 5,500,000 shares during the period. Acuta Capital Partners LLC increased its holdings in shares of Unicycive Therapeutics by 16.4% during the fourth quarter. Acuta Capital Partners LLC now owns 2,303,000 shares of the company’s stock valued at $1,829,000 after acquiring an additional 323,801 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Unicycive Therapeutics by 30.3% during the fourth quarter. Geode Capital Management LLC now owns 524,487 shares of the company’s stock valued at $417,000 after acquiring an additional 122,089 shares in the last quarter. Institutional investors and hedge funds own 40.42% of the company’s stock.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.